Literature DB >> 26298543

Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Birgitta Sander1, Leticia Quintanilla-Martinez2, German Ott3, Luc Xerri4, Isinsu Kuzu5, John K C Chan6, Steven H Swerdlow7, Elias Campo8.   

Abstract

Mantle cell lymphoma (MCL) is a distinctive lymphoma type generally characterized by the presence of CCND1 translocation and overexpression of cyclin D1. MCL usually presents with advanced stage and rapid clinical progression. The diagnosis is in most instances uncomplicated but cases with variant morphologies or immunophenotypes, especially cyclin D1-negative cases, may cause diagnostic difficulties. During the mantle cell lymphoma (MCL) session at the European Association of Haematopathology/Society for Hematopathology workshop 2014 held in Istanbul, Turkey, submitted cases illustrated interesting features such as unusual morphology or immunophenotypes. In several submitted cases of cyclin D1-positive MCL, CCND1 rearrangement could not be detected by t(11;14)(q13;q32) dual-color dual-fusion FISH but was suggested by CCND1 break-apart probes, and advantages and disadvantages of different FISH probes were highlighted. Three cyclin D1-negative MCL cases were submitted. These were identified by SOX11 immunohistochemistry and found to carry CCND2 translocations and/or to express high levels of cyclin D2 mRNA. Features associated with aggressive clinical course were presented including high expression of p53 protein and MYC aberrations. The need to integrate histological, immunophenotypic, genetic, and clinical data to arrive at the correct diagnosis was emphasized.

Entities:  

Keywords:  Aggressive; FISH; Genetic aberrations; Immunophenotype; Indolent; Mantle cell lymphoma; Morphology

Mesh:

Year:  2015        PMID: 26298543     DOI: 10.1007/s00428-015-1840-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  74 in total

1.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

Authors:  Lina Nygren; Stefanie Baumgartner Wennerholm; Monika Klimkowska; Birger Christensson; Eva Kimby; Birgitta Sander
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

2.  Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression.

Authors:  Christian Herens; Frédéric Lambert; Leticia Quintanilla-Martinez; Bettina Bisig; Carine Deusings; Laurence de Leval
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

Review 3.  The complex landscape of genetic alterations in mantle cell lymphoma.

Authors:  Cristina Royo; Itziar Salaverria; Elena M Hartmann; Andreas Rosenwald; Elías Campo; Sílvia Beà
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

Review 4.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

5.  Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants.

Authors:  A Majlis; W C Pugh; M A Rodriguez; W F Benedict; F Cabanillas
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

6.  Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.

Authors:  Joel F Gradowski; Rachel L Sargent; Fiona E Craig; Kathleen Cieply; Kim Fuhrer; Carol Sherer; Steven H Swerdlow
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

7.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.

Authors:  Itziar Salaverria; Andreas Zettl; Sílvia Beà; Victor Moreno; Joan Valls; Elena Hartmann; German Ott; George Wright; Armando Lopez-Guillermo; Wing C Chan; Dennis D Weisenburger; Randy D Gascoyne; Thomas M Grogan; Jan Delabie; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Andreas Rosenwald; Elias Campo
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

8.  Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis.

Authors:  Tiemo Katzenberger; Dirk Kienle; Stephan Stilgenbauer; Sylvia Höller; Carolin Schilling; Uwe Mäder; Bernhard Puppe; Celine Petzoldt; Sandrine Sander; Lars Bullinger; Heike Stöcklein; Jörg Kalla; Elena Hartmann; Patrick Adam; M Michaela Ott; Hans-Konrad Müller-Hermelink; Andreas Rosenwald; German Ott
Journal:  Br J Haematol       Date:  2008-06-28       Impact factor: 6.998

9.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

10.  The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements.

Authors:  S H Swerdlow; L R Zukerberg; W I Yang; N L Harris; M E Williams
Journal:  Am J Surg Pathol       Date:  1996-05       Impact factor: 6.394

View more
  25 in total

Review 1.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

Review 2.  Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Authors:  Elaine S Jaffe; Paul M Barr; Sonali M Smith
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

3.  Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.

Authors:  Sietse M Aukema; Giorgio A Croci; Reiner Siebert; Wolfram Klapper; Susanne Bens; Kathrin Oehl-Huber; Rabea Wagener; German Ott; Andreas Rosenwald; Philip M Kluin; Eva van den Berg; Anneke G Bosga-Bouwer; Mels Hoogendoorn; Eva Hoster; Iris Bittmann; Inga Nagel; Eva M Murga Penas; Markus Kreuz; Julia Bausinger; Wilfried Belder; Ilske Oschlies; Martin J S Dyer; Sandrine Jayne
Journal:  Virchows Arch       Date:  2021-02-02       Impact factor: 4.064

4.  Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Authors:  James N Gerson; Elizabeth Handorf; Diego Villa; Alina S Gerrie; Parv Chapani; Shaoying Li; L Jeffrey Medeiros; Michael I Wang; Jonathon B Cohen; Oscar Calzada; Michael C Churnetski; Brian T Hill; Yazeed Sawalha; Francisco J Hernandez-Ilizaliturri; Shalin Kothari; Julie M Vose; Martin A Bast; Timothy S Fenske; Swapna Narayana Rao Gari; Kami J Maddocks; David Bond; Veronika Bachanova; Bhaskar Kolla; Julio Chavez; Bijal Shah; Frederick Lansigan; Timothy F Burns; Alexandra M Donovan; Nina Wagner-Johnston; Marcus Messmer; Amitkumar Mehta; Jennifer K Anderson; Nishitha Reddy; Alexandra E Kovach; Daniel J Landsburg; Martha Glenn; David J Inwards; Reem Karmali; Jason B Kaplan; Paolo F Caimi; Saurabh Rajguru; Andrew Evens; Andreas Klein; Elvira Umyarova; Bhargavi Pulluri; Jennifer E Amengual; Jennifer K Lue; Catherine Diefenbach; Richard I Fisher; Stefan K Barta
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544

Review 5.  Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.

Authors:  Sílvia Beà; Virginia Amador
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

6.  A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.

Authors:  Daisuke Kurita; Kengo Takeuchi; Sumiko Kobayashi; Atsuko Hojo; Yoshihito Uchino; Masashi Sakagami; Shimon Ohtake; Hiromichi Takahashi; Katsuhiro Miura; Noriyoshi Iriyama; Masahiko Sugitani; Hiroaki Miyoshi; Yoshihiro Hatta; Koichi Ohshima; Masami Takei
Journal:  Virchows Arch       Date:  2016-07-25       Impact factor: 4.064

Review 7.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

8.  CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Authors:  Zhihong Hu; Yi Sun; Ellen J Schlette; Guilin Tang; Shaoying Li; Jie Xu; C Cameron Yin; Ken H Young; Keyur Pravinchandra Patel; Roberto N Miranda; Maitrayee Goswami; Michael Wang; Jeffrey L Jorgensen; L Jeffrey Medeiros; Sa A Wang
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

9.  B-cell lymphomas with discordance between pathological features and clinical behavior.

Authors:  Laurence de Leval; Christiane Copie-Bergman; Andreas Rosenwald; Lisa Rimsza; Stefania Pittaluga; Bettina Bisig; Stefan Dirnhofer; Fabio Facchetti; Stefano Pileri; Falko Fend; Andrew Wotherspoon
Journal:  Virchows Arch       Date:  2017-06-01       Impact factor: 4.064

10.  Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.

Authors:  Carla Fuster; David Martín-Garcia; Olga Balagué; Alba Navarro; Ferran Nadeu; Dolors Costa; Miriam Prieto; Itziar Salaverria; Blanca Espinet; Alfredo Rivas-Delgado; Maria José Terol; Eva Giné; Pilar Forcada; Margaret Ashton-Key; Xose S Puente; Steven H Swerdlow; Sílvia Beà; Elias Campo
Journal:  Haematologica       Date:  2019-11-21       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.